Motif Bio PLC

Motif Bio to present positive iclaprim drug data in the US this week

The biopharma firm said trials confirmed that iclaprim is non-inferior to vancomycin and significantly safer

Iclaprim could be a valuable treatment option for patients with wound infections

Motif Bio PLC (LON:MTFB) plans to present data showing the safety and efficacy of its next-generation antibiotic iclaprim compared to the current gold standard medication, vancomycin.

The company said on Wednesday that it plans to present its data and the results of the REVIVE Phase 3 trials at IDWeek being held in San Francisco later this week.

READ: Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard

Motif Bio said 50% (602 out of 1198) of the REVIVE intent-to-treat (ITT) population had wound infections and that iclaprim was just as effective as vancomycin, based on an early clinical response of a subgroup of patients with wound infections. 

The company also repeated that its drug was found not to negatively affect patients’ kidney function, a key issue for some people taking rival treatments. None of the patients taking iclaprim showed signs of kidney toxicity, compared to two patients in the vancomycin arm.

"Wound infections, including surgical site infections, can be difficult to treat and it was important to see that iclaprim was non-inferior to standard of care in treating these types of infections,” G. Ralph Corey, MD, Vice Chair for Education and Global Health and Gary Hock Professor at Duke University School of Medicine and a principal investigator in the REVIVE-2 trial, said in a statement.

“Iclaprim, if approved, could be a valuable treatment option for patients with wound infections … including patients with co-morbidities known to increase the risk of vancomycin-associated acute kidney injury, such as renal impairment, diabetes and obesity," he added.

Shares in Motif Bio were flat at 34.95p in early trade.

Quick facts: Motif Bio PLC

Price: £0.03

Market: AIM
Market Cap: £8.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

on 19/8/19

2 min read